

Accepted Manuscript

Title: Synthesis and evaluation of geometric analogs of $1\alpha,25$ -dihydroxyvitamin D₂ as potential therapeutics

Author: Narasimha Rao Bolla Aoife Corcoran Kaori Yasuda
Michał Chodyński Krzysztof Krajewski Piotr Cmoch Ewa
Marcinkowska Geoffrey Brown Toshiyuki Sakaki Andrzej
Kutner



PII: S0960-0760(15)30057-1
DOI: <http://dx.doi.org/doi:10.1016/j.jsbmb.2015.08.025>
Reference: SBMB 4488

To appear in: *Journal of Steroid Biochemistry & Molecular Biology*

Received date: 11-6-2015
Revised date: 18-8-2015
Accepted date: 24-8-2015

Please cite this article as: Narasimha Rao Bolla, Aoife Corcoran, Kaori Yasuda, Michał Chodyński, Krzysztof Krajewski, Piotr Cmoch, Ewa Marcinkowska, Geoffrey Brown, Toshiyuki Sakaki, Andrzej Kutner, Synthesis and evaluation of geometric analogs of $1\alpha,25$ -dihydroxyvitamin D₂ as potential therapeutics, *Journal of Steroid Biochemistry and Molecular Biology* <http://dx.doi.org/10.1016/j.jsbmb.2015.08.025>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Synthesis and evaluation of geometric analogs of $1\alpha,25$ -dihydroxyvitamin D_2 as potential therapeutics

Narasimha Rao Bolla^{a*}, Aoife Corcoran^b, Kaori Yasuda^c, Michał Chodyński^a, Krzysztof Krajewski^a, Piotr Cmoch^a, Ewa Marcinkowska^b, Geoffrey Brown^d, Toshiyuki Sakaki^c, Andrzej Kutner^a

^aPharmaceutical Research Institute, 8 Rydygiera, 01-793 Warsaw, Poland

^bFaculty of Biotechnology, University of Wrocław, 14a Joliot-Curie, 50-383 Wrocław, Poland

^cDepartment of Biotechnology, Faculty of Engineering, Toyama Prefectural University 5180 Kurokawa, Imizu, Toyama 939-0398, Japan

^dSchool of Immunity and Infection, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, West Midlands B15 2TT, UK

*Corresponding author: Narasimha Rao Bolla, +48 22 456 3930; n.bolla@ifarm.eu

Graphical abstract

fx1

Highlights:

- Analogs of $1\alpha,25$ -dihydroxyvitamin D_2 were synthesized by an improved strategy
- New (24Z) geometric isomers, PRI-1916 and PRI-1917, were obtained and identified
- The structures were determined by ^1H and ^{13}C NMR, using COSY, HSQC and HMBC
- Binding affinities were determined by a fluorescence polarization competition assay
- New analogs were much more resistant to CYP24A1 than $1\alpha,25$ -dihydroxyvitamin D_2

A B S T R A C T

An improved convergent strategy was developed for the synthesis of the previously obtained side-chain extended and rigidified analogs of $1\alpha,25$ -dihydroxyvitamin D_2 , PRI-1906 and PRI-1907. New (24Z) geometric isomers of the analogs, PRI-1916 and PRI-1917, were also obtained and identified. These side-chain isomers were separable by flash chromatography, as C-25 alcohols, from the synthetic precursors of PRI-1906 and PRI-1907, respectively. The structures of new analogs were determined by advanced techniques of ^1H and ^{13}C NMR,

including COSY, HSQC and HMBC sequences. Binding affinities of the geometric analogs PRI-1906 and PRI-1916 and their respective C-26, C-27 homologs PRI-1907 and PRI-1917 for the full-length human vitamin D receptor were determined by a fluorescence polarization competition assay. The binding affinity of (24Z) methyl analog PRI-1906 was much higher than that of (24E) analog PRI-1906, while the affinity of (24Z) ethyl analog PRI-1917 was lower than that of the respective PRI-1907. Investigation of the metabolism of these compounds by human CYP24A1 revealed they are much more resistant to CYP24A1 than $1\alpha,25$ -dihydroxyvitamin D₂, indicating they could have longer-term biological effects on target tissues.

This article is part of a special issue entitled “18th Workshop on Vitamin D”.

Keywords:

analogs of $1\alpha,25$ -dihydroxyvitamin D₂

modified Julia olefination

NOE effects

VDR binding affinity

CYP24A1 metabolic stability

1. Introduction

Over several decades numerous laboratories have endeavored to unravel the complexity of the molecular mechanisms relating to the functions of the vitamin D system [1]. In part, this has been driven by interests in identifying synthetic analogs with a desired selective activity profile for use as therapeutics [2] against not only metabolic, bone and skin diseases but also to treat cancer, cardiovascular disorders, infectious and immune diseases. In regard to these efforts we have pursued the design, synthesis and biological evaluation [3,4,5] of analogs of $1\alpha,25$ -dihydroxyvitamin D₂ (1,25D₂, Fig. 1).

Initially, we observed that out of our series of four side-chain extended and branched analogs of 1,25D₂, compounds PRI-1906 and PRI-1907, with two methyl and two ethyl at C-25, respectively, were able to moderately inhibit proliferation and significantly activate expression of CYP24A1 mRNA in prostate cancer cells PC-3 [6].

We also reported, for the first time, that inhibition of cellular caspase activity can induce differentiation of AML blasts and enhance vitamin D-induced cell differentiation of these cells. Differentiation induced by $1\alpha,25$ -dihydroxyvitamin D₃ (1,25D₃, Fig. 1) or its analog PRI-1906 was enhanced by pan-caspase inhibitor QVD (N-(2-quinolyl)-L-valyl-L-aspartyl-(2,6-difluorophenoxy) methylketone) to a varying degree, depending on the subtype of the leukemia [7].

Our analogs PRI-1906 and PRI-1907 have increased cell-differentiation activities against *ex-vivo* blast cells from patients with acute myeloid leukemia as compared to 1,25D₃ [8]. Our study also revealed a high variability as to the susceptibility of individual patients' blasts to our vitamin D₂ analogs.

Very recently, we have introduced 19-*nor* modification into the structure of our analogs PRI-1906 and PRI-1907. We synthesized analogs PRI-5201 and PRI-5202 [9] which have increased differentiating activity as compared to 1,25D₃ and PRI-1907 [10]. In current attempts to optimize the side-chain geometry of these analogs, for the specific hydrogen bonding interactions of 25-hydroxyl with the amino acids residues of LBD of VDR [11], we have now obtained (22*E*,24*Z*)-analogs of 1,25D₂, PRI-1916 and PRI-1917 (Fig. 2) and tested them for affinity for VDR. Metabolic stability of our analogs as to degradation by the enzyme CYP24A1 [12,13] was also determined in order to select the most resistant analog [14] for further biological evaluation.

2. Results and discussion

2.1. Synthesis of analogs PRI-1906, PRI-1907, PRI-1916 and PRI-1917

Analog PRI-1906 and PRI-1907 were first synthesized by Julia olefination of C-22 vitamin D phenylsulphone [15].

However, the reductive dehydroxy-desulfonylation of the resulting phenylsulfonyl hydroxy ester with sodium amalgam was a very inefficient process. We have now synthesized these analogs by a modified Julia olefination [16,17,18] of C-22 benzothiazoyl sulfone (**1**, Scheme 1) and the side-chain aldehyde **2** [4]. In this process, the intermediate alkoxide is more reactive, than for the respective phenylsulfone, and undergoes a Smiles rearrangement to the respective sulfinate salt. This process is accompanied by the spontaneous elimination of sulfur dioxide to give the conjugated (22*E*)-ester **3** directly. Based on the mechanism of a modified Julia olefination we expected to get, as a result of olefination and Grignard reaction, (22*Z*)-isomers **12** and **13** (Fig. 3) as by-products. However, very favorably, ester **3** was obtained as a

single product, not contaminated with its (22Z)-isomer. This was proved by a single signal of 18-CH₃ in ¹H NMR. Grignard reaction of ester **3** with MeMgBr and EtMgBr, gave the respective alcohols **4** and **6**. Quite unexpectedly, in the course of the Grignard reaction, the (24Z)-isomers **5** and **7** were also formed, as isomerization by-products.

2.2. Structural assignment of analogs PRI-1916 and PRI-1917

The ¹H and ¹³C NMR spectra of PRI-1917 and PRI-1907, supported by MS data, indicated [19] that both compounds are geometric isomers. The most significant differences were observed in the range 7.00-5.00 ppm in the ¹H NMR spectra and 140-120 ppm in the ¹³C NMR spectra. Based on the advanced 2D NMR experiments (including COSY, HSQC and HMBC sequences) all signals in the ¹H and ¹³C NMR spectra were assigned to the respective protons and carbon atoms. In the ¹H NMR spectrum of PRI-1907 protons at 5.48 (H-22) and 5.97 ppm (H-23) were of (22E)-geometry, as the coupling constant ³J(H22-H23) was equal to 15 Hz. The same was the value of the ³J(H22-H23) for PRI-1917, indicating unequivocally that both, PRI-1907 and PRI-1917 are (22E)-isomers. The same was also a case for analogs PRI-1906 and PRI-1916. 1D Selective ¹H NOESY sequence allowed us to determine the mutual relation between all protons in the side-chain of analogs PRI-1907 (Fig. 4) and PRI-1917 (Fig. 5), as well as PRI-1906 and PRI-1916.

Irradiation of H-23 proton at 5.97 ppm in the ¹H NMR spectrum of PRI-1907 [19] gave the NOE enhancement at H-24a proton at 5.28 ppm, whereas irradiation of H-22 proton at 5.48 ppm resulted in a strong NOE effect at C-28 methyl (1.92 ppm). The same NOE effect was also observed for H-22 proton at 5.52 ppm and C-28 methyl (1.82 ppm) for PRI-1917. On the contrary, irradiation of the isolated signal at 7.00 ppm in PRI-1917 did not result in any NOE effects in this range of ¹H NMR shifts. These NOE enhancements clearly indicated (22E) geometry [20] in both PRI-1907 and PRI-1917, whereas the C-24 geometry was (24E) and (24Z) for PRI-1907 and PRI-1917, respectively. The same geometries were found for PRI-1906 and PRI-1916, respectively.

2.3. Human VDR binding assay

Binding affinities of the new analogs PRI-1916 and PRI-1917 for human full-length VDR were evaluated using a 1,25D3 assay kit and compared to that of 1,25D3, PRI-1906 and PRI-1907 [10]. In this fluorescence polarization competition assay, VDR was added to a

fluorescent VDR ligand to form a receptor/tracer complex giving a high polarization value. This complex was then added to individual test compounds to displace the tracer from the complex. The activity of each compound is shown (Table 1) as a percentage whereby the activity of 1,25D3 was normalized to 100%. This data was derived from dose-response curves (data not shown)

2.4. Metabolic resistance of analogs to CYP24A1

The metabolism of each analog by human CYP24A1 (hCYP24A1) was analyzed using the membrane fraction prepared from the recombinant *E. coli* cells expressing hCYP24A1 [21]. The conversion ratios of each analog to its metabolites for PRI-1906, PRI-1916, PRI-1907 and PRI-1917 were 2.3, 11, 0.8 and 10%, respectively (Table 2, Fig. 6 and SI). Meanwhile, native 1,25D3 and 1,25D2 were sequentially metabolized by CYP24A1 [21,22], and their conversion ratios were 49% and 39%, respectively. These results indicated that all of the analogs are more resistant to CYP24A1-dependent metabolism than native 1,25D3 and 1,25D2. In particular, PRI-1906 and PRI-1907 showed a remarkable resistance against CYP24A1. Since CYP24A1 is transcriptionally induced by VDR agonists in the target tissues to inactivate them, our analogs, especially PRI-1906 and PRI-1907, should have longer-term biological effects in the target tissues [23].

The complete evaluation of biological activities of our analogs is underway in this laboratory, according to the previously outlined scheme [3].

3. Conclusions

We synthesized side-chain extended and homologated (24Z)-analogs PRI-1916 and PRI-1917 of 1,25D2 and have developed improved method for the synthesis of our leading 1,25D2 analogs PRI-1906 and PRI-1907, by a modified Julia olefination and from the previously developed C-22 benzothiazoyl sulfone as the advanced intermediate. New analogs were separable from their geometric isomers by flash chromatography at the level of C-25 alcohols. The structures of side-chains of analogs PRI-1916 and PRI-1917 was assigned by advanced techniques of ^1H and ^{13}C NMR. Binding affinities of the new analogs for the human full-length VDR were determined using fluorescence polarization competition assay. The VDR binding affinity of new analogs were lower than that of 1,25D3. Furthermore, introducing (24Z) geometry increased the affinity for methyl analog PRI-1916, as compared

to (24*E*) analog PRI-1906, while it decreased the affinity for ethyl analog PRI-1917, as compared to (24*E*) analog PRI-1907, meaning that the terminal alkyls at C-25 strongly influence the binding affinity.

Isomerization of side-chain (24*E*)-analogs of 1,25D₂ (PRI-1906 and PRI-1907) at C24 resulted in the lowered resistance to metabolism by CYP24A1, although (24*Z*)-analogs (PRI-1916 and PRI-1917) were still more resistant than native 1,25D₂ and 1,25D₃. These results reveal that side-chain extended and rigidified analogs of 1,25D₂, especially (24*E*)-analogs, may be useful to elicit longer-term biological effects against target tissues.

Acknowledgements

The research leading to these results has received funding from the People Program (Marie Curie Actions) of the European Union's Seventh Framework Program FP7/2007-2013 under Research Executive Agency grant agreement No. 315902. The authors (NBR and AC) gratefully acknowledge receipt of a Marie Curie Research Associate post. EM, GB and AK are partners within the Marie Curie Initial Training Network DECIDE (Decision-making within cells and differentiation entities therapies). This work was presented in part at the 18th Workshop on Vitamin D, in Delft, The Netherlands, April 21-24, 2015.

References

- [1] H.F. DeLuca, Is there more to learn about functional vitamin D metabolism, *J. Steroid Biochem. Mol. Biol.* 148 (2015) 3-6.
- [2] D. Feldman, A.V. Krishnan, S. Swami, E. Giovannucci, B.J. Feldman, The role of vitamin D in reducing cancer risk and progression, *Nature Rev. Cancer* 14 (2014) 342-357.
- [3] S. Nadkarni, M. Chodynski, A. Corcoran, E. Marcinkowska, G. Brown, A. Kutner, Double point modified analogs of vitamin D as potent activators of vitamin D receptor, *Curr. Pharm. Design* 21 (2015) 1741-1763.
- [4] M. Milczarek, M. Chodynski, B. Filip-Psurska, A. Martowicz, M. Krupa, K. Krajewski, A. Kutner, J. Wietrzyk, Synthesis and biological activity of diastereomeric and geometric analogs of calcipotriol, PRI-2202 and PRI-2205, against human HL-60 leukemia and MCF-7 breast cancer cells, *Cancers* 5 (2013) 1355-1378.
- [5] B. Filip, M. Milczarek, J. Wietrzyk, M. Chodynski, A. Kutner, Antitumor properties of (5*E*,7*E*) analogs of vitamin D₃, *J. Steroid Biochem. Mol. Biol.* 121 (2010) 399-402.
- [6] H. Burska, A. Klopot, M. Kielbinski, A. Chrobak, E. Wijas, A. Kutner, E. Marcinkowska, Structure-function analysis of vitamin D₂ analogs as potential inducers of

leukemia differentiation and inhibitors of prostate cancer proliferation, *J. Steroid Biochem. Mol. Biol.* 126 (2011) 46-54.

[7] X. Chen-Deutsch, A. Kutner, J. S. Harrison, G.P. Studzinski, The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells, *Leukemia Res.* 36 (2012) 884-888.

[8] H. Bauraska, M. Kielbinski, P. Biecek, O. Haus, B. Jazwiec, A. Kutner, E. Marcinkowska, Monocytic differentiation induced by side-chain modified analogs of vitamin D in *ex vivo* cells from patients with acute myeloid leukemia, *Leukemia Res.* 38 (2014) 638-647.

[9] A. Pietraszek, M. Malinska, M. Chodynski, M. Krupa, K. Krajewski, P. Cmoch, K. Wozniak, A. Kutner; Synthesis and crystallographic study of analogs of 1,25-dihydroxyergocalciferol, *Steroids* 78 (2013) 1003-1014.

[10] A. Corcoran, M.A. Bermudez, S. Seoane, R. Perez-Fernandez, M. Krupa, A. Pietraszek, M. Chodyński, A. Kutner, G. Brown, E. Marcinkowska, Biological evaluation of new vitamin D₂ analogs, *J. Steroid Biochem. Mol. Biol.* submitted to this issue.

[11] I. Billas, D. Moras, Allosteric Controls of nuclear receptor function in the regulation of transcription, *J. Mol. Biol.* 425 (2013) 2317-2329.

[12] M. Takano, D. Sawada, K. Yasuda, M. Nishikawa, A. Takeuchi, K. Takagi, K. Horie, G.S. Reddy, T.C. Chen, T. Sakaki, A. Kittaka, Synthesis and metabolic studies of 1 α ,2 α ,25-, 1 α ,4 α ,25- and 1 α ,4 β ,25-trihydroxyvitamin D₃, *J. Steroid Biochem. Mol. Biol.* 148 (2015) 34-37.

[13] M. Takano, S. Ohya, K. Yasuda, M. Nishikawa, A. Takeuchi, D. Sawada, T. Sakaki, A. Kittaka, Synthesis and biological activity of 1 α ,2 α ,25-trihydroxyvitamin D₃: active metabolite of 2 α -(3-hydroxypropoxy)-1 α ,25-dihydroxyvitamin D₃ by human CYP3A4, *Chem. Pharm. Bull.* 62 (2014) 182-184.

[14] T. Sakaki, K. Yasuda, A. Kittaka, K. Yamamoto, T.C. Chen, CYP24A1 as a potential target for cancer therapy, *Anticancer Agents Med. Chem.* 14 (2014) 97-108.

[15] M. Chodynski, J. Wietrzyk, E. Marcinkowska, A. Opolski, W. Szelejewski, A. Kutner, Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D₂, (24*E*)-(1*S*)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners, *Steroids* 67 (2002) 789-798.

[16] A. Glebocka, R.R. Sicinski, L.A. Plum, M. Clagett-Dame, H.F. DeLuca, New 2-alkylidene 1 α ,25-dihydroxy-19-norvitamin D₃ analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives, *J. Med. Chem.* 49 (2006) 2909-2920.

[17] A. Kutner, Convergent synthesis of vitamin D analogs, *Przem. Chem.* 85 (2006) 322-329 (Pol).

[18] A. Kutner, J. Martynow, M. Chodynski, W. Szelejewski, H. Fitak, M. Krupa, Process of preparation of 24-alkyl analogs of cholecalciferol and intermediate compounds, US 7915241 B2 (2011); CA 2003-2481909.

[19] ^1H and ^{13}C NMR data of new analogs:

9, PRI-1916: ^1H NMR (600 MHz, CD_3OD , 25.8 °C, TMS) δ = 6.988 (d, J = 15.6 Hz, 1H, 23-H), 6.324 (d, J = 11.4 Hz, 1H, 7-H), 6.084 (d, J = 10.8 Hz, 1H, 6-H), 5.523 (dd, J_1 = 15 Hz, J_2 = 9 Hz, 1H, 22-H), 5.377 (s, 1H, 24a-H), 5.286 (s, 1H, 19E-H), 4.897 (s, 1H, 19Z-H), 4.349 (t, J_1 = J_2 = 6 Hz, 1H, 1-H), 4.126 (t, J_1 = J_2 = 5.4 Hz, 1H, 3-H), 1.774 (s, 3H, 28- CH_3), 1.352 (s, 6H, 26- CH_3 , 27- CH_3), 1.078 (d, J = 7.2 Hz, 3H, 21- CH_3), 0.601 (s, 3H, 18- CH_3); ^{13}C NMR (600 MHz, CD_3OD , 25.8 °C, TMS): δ = 149.79 (C=CH₂, C-10), 142.33 (C=C H₂, C-8), 139.29 (C=CH₂, C-5), 136.39 (C=CH₂, C-24a), 135.78 (C=CH₂, C-23), 133.72 (C=CH₂, C-24), 126.84 (C=CH₂, C-22), 124.83 (C=CH₂, C-6), 119.05 (C=CH₂, C-7), 112.07 (C=CH₂, C-19), 77.10 (C-OH, C-25), 71.46 (C-OH, C-1), 67.38 (C-OH, C-3), 57.72 (C-CH₂, C-14), 57.59 (C-CH₂, C-17), 46.97 (C-CH₂, C-4), 46.15 (C-CH₂, C-13), 43.70 (C-CH₂, C-2), 42.26 (C-CH₃, C-20), 41.72 (C-CH₂, C-12), 29.98 (C-CH₂, C-9), 28.88 (C-CH₂, C-16), 24.60 (C-CH₂, C-15), 23.25 (C-CH₂, C-11), 21.29 (C-21), 21.19 (C-28), 12.96 (C-18), 12.69 (C-26), 12.68 (C-27). HRMS: calc'd for $\text{C}_{29}\text{H}_{44}\text{O}_3$ [$\text{M}+\text{Na}$]⁺, 463.3188 found: 463.3190.

11, PRI-1917: ^1H NMR (600 MHz, CD_3OD , 25.8 °C, TMS): δ = 6.997 (d, J = 15.6 Hz, 1H, 23-H), 6.321 (d, J = 11.4 Hz, 1H, 7-H), 6.082 (d, J = 11.4 Hz, 1H, 6-H), 5.515 (dd, J_1 = 15.6 Hz, J_2 = 8.4 Hz, 1H, 22-H), 5.284 (s, 1H, 24a-H), 5.168 (s, 1H, 19E-H), 4.896 (s, 1H, 19Z-H), 4.347 (t, J_1 = 6, J_2 = 5.4 Hz, 1H, 1-H), 4.123 (t, J_1 = 6.6 Hz, J_2 = 4.8 Hz, 1H, 3-H), 1.811 (s, 3H, 28- CH_3), 1.441-1.372 (m, 6H, 26- CH_3 , 27- CH_3), 1.078 (d, J = 7.2 Hz, 3H, 21- CH_3), 0.601 (s, 3H, 18- CH_3). ^{13}C NMR (600 MHz, CD_3OD , 25.8 °C, TMS): δ = 149.79 (C=CH₂, C-10), 142.42 (C=C H₂, C-8), 138.00 (C=CH₂, C-5), 135.73 (C=CH₂, C-24a), 135.00 (C=CH₂, C-23), 133.58 (C=CH₂, C-24), 127.84 (C=CH₂, C-22), 124.85 (C=CH₂, C-6), 119.02 (C=CH₂, C-7), 112.07 (C=CH₂, C-19), 77.32 (C-OH, C-25), 71.48 (C-OH, C-1), 67.39 (C-OH, C-3), 57.87 (C-CH₂, C-14), 57.60 (C-CH₂, C-17), 46.96 (C-CH₂, C-4), 46.15 (C-CH₂, C-13), 43.69 (C-CH₂, C-2), 42.24 (C-CH₃, C-20), 41.74 (C-CH₂, C-12), 35.49 (C-CH₃, C-26), 35.35 (C-CH₃, C-27), 29.98 (C-CH₂, C-9), 28.79 (C-CH₂, C-16), 24.61 (C-CH₂, C-15), 23.27 (C-CH₂, C-11), 21.90 (C-21), 21.31 (C-28), 12.68 (C-18), 8.59 (C-26'), 8.522 (C-27'). HRMS: calc'd for $\text{C}_{31}\text{H}_{48}\text{O}_3$ [$\text{M}+\text{Na}$]⁺, 491.3501 found: 491.3502.

- [20] J. Wietrzyk, M. Chodynski, H. Fitak, E. Wojdat, A. Kutner, A. Opolski; Antitumor properties of diastereomeric and geometric analogs of vitamin D₃, *Anti-Cancer Drugs* 18 (2007) 447-457.
- [21] T. Kusudo, T. Sakaki, D. Abe, T. Fujishima, A. Kittaka, H. Takayama, S. Hatakeyama, M. Ohta, K. Inouye, Metabolism of A-ring diastereomers of 1 α ,25-dihydroxyvitamin D₃ by CYP24A1, *Biochem. Biophys. Res. Commun.* 321 (2004) 774-782.
- [22]. N. Urushino, K. Yasuda, S. Ikushiro, M. Kamakura, M. Ohta, T. Sakaki, Metabolism of 1 α ,25-dihydroxyvitamin D₂ by human CYP24A1, *Biochem. Biophys. Res. Commun.* 384 (2009) 144-148.
- [23]. T. Sakaki, K. Yasuda, A. Kittaka, K. Yamamoto, T. C. Chen, CYP24A1 as a potential target for cancer therapy, *Anticancer Agents Med. Chem.* 14 (2014) 97-108.

Scheme 1. Convergent synthesis of side-chain (22*E*,24*E*)-analogs of 1 α ,25-dihydroxyvitamin D₂ (**8**, PRI-1906 and **10**, PRI-1907) and (22*E*,24*Z*)-analogs of 1 α ,25-dihydroxyvitamin D₂ (**9**, PRI-1916 and **11**, PRI-1917).

Fig. 1. Structures of 1 α ,25-dihydroxyvitamin D₃ and 1 α ,25-dihydroxyvitamin D₂.

Fig. 2. Structures of side-chain homologated and unsaturated analogs of 1 α ,25-dihydroxyvitamin D₂.

Fig. 3. Structures of hypothetical (22*Z*)-analogs of 1 α ,25-dihydroxyvitamin D₂.

Fig. 4. Structure of **10** (PRI-1907) showing NOE assignments for characteristic protons in the side-chain.

Fig. 5. Structure of **11** (PRI-1917) showing NOE assignments for characteristic protons in the side-chain.

Fig. 6. HPLC profiles of 1,25D₃, 1,25D₂, analogs PRI-1906 and PRI-1916 and their metabolites generated by human CYP24A1. The peaks marked with arrows indicate putative metabolites. Profiles for PRI-1907 and PRI-1917 are included in the supporting information (SI).

Table 1

Binding affinity of analogs for the full-length human vitamin D receptor in a fluorescence polarization competition assay.

Compound	1,25D3	PRI-1906	PRI-1916	PRI-1907	PRI-1917
IC ₅₀	2.232e ⁻⁰⁹	5.561e ⁻⁰⁰⁸	6.048e ⁻⁰⁹	6.172e ⁻⁰⁹	6.848 e ⁻⁰⁰⁸
Relative binding affinity ^a	100	4	37	38	3

^aPotency of 1,25D3 normalized to 100

Table 2

Metabolic conversion of active forms of vitamins D and of analogs by human CYP24A1

Compound	1,25D3	1,25D2	PRI-1906	PRI-1916	PRI-1907	PRI-1917
Metabolic conversion ^a (%)	49	39	2.3	11	0.8	10

^aData represent the mean of at least 2 independent experiments.